Clinical Trials Logo

Malignant Fibrous Histiocytoma clinical trials

View clinical trials related to Malignant Fibrous Histiocytoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00503295 Completed - Osteosarcoma Clinical Trials

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.

NCT ID: NCT00400569 Completed - Leiomyosarcoma Clinical Trials

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This is an open label single site Phase II clinical trial to identify a potentially promising therapy dose for Sunitinib malate. The study drug will be taken orally once daily on days 1 through 28 of each 42 day cycle. Treatment will be continued until there is either disease progression or cumulative/acute toxicity. All patients with unresectable or metastatic soft tissue sarcoma (STS): leiomyosarcoma, liposarcoma, fibrosarcoma, and malignant fibrous histiocytoma (MFH) seen at the Moffitt Cancer Center will be screened for eligibility to be enrolled in the study.